Secondary Sclerosing Cholangitis in Critically Ill Patients

Key facts

Sponsor

Medical University of Graz

Principal Investigator

Vanessa Stadlbauer, MD

Medical University of Graz

Enrollment

140 enrolled

Eligibility

18-99 years · All sexes

Timeline

2015 – 2028

Study locations (1)

• Department of Internal Medicine, Medical University of Graz, Graz, Austria

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Sclerosing cholangitis

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07317193
  DEFINING THE GENETIC DRIVERS OF ADULT-ONSET CHOLESTATIC LIVER DISEASE
  Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
• RECRUITINGPHASE1NCT06825559
  Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease
  Zydus Therapeutics Inc.
• RECRUITINGNCT06781242
  Genotype-phenotype Relationship Between Cryptogenic Cholestasis and Familial Intrahepatic Cholestasis
  IRCCS Azienda Ospedaliero-Universitaria di Bologna
• ACTIVE NOT RECRUITINGNANCT02601417
  The Necessity of Bile Cultures in Patients With Acute Cholangitis
  Seoul National University Hospital

See all trials for Sclerosing cholangitis →